Affordable Access

deepdyve-link
Publisher Website

The risk of stroke or clinical impairment after stereotactic radiosurgery for ARUBA-eligible patients.

Authors
  • Pollock, Bruce E
  • Link, Michael J
  • Brown, Robert D
Type
Published Article
Journal
Stroke
Publisher
Ovid Technologies Wolters Kluwer -American Heart Association
Publication Date
Feb 01, 2013
Volume
44
Issue
2
Pages
437–441
Identifiers
DOI: 10.1161/STROKEAHA.112.670232
PMID: 23287780
Source
Medline
License
Unknown

Abstract

The observed risk of stroke or death after SRS was approximately 2% per year for the first 5 years after SRS, declining to 0.2% annually for years 6 to 10. Patients with small volume BAVM may benefit from SRS compared with the natural history of unruptured BAVM over the planned follow-up interval of the ARUBA trial (5-10 years).

Report this publication

Statistics

Seen <100 times